Member Info for fastduckharry

I have SBDS on my watchlists. Am shocked at how they lost the money. Makes me wonder if they had any security at all. To dismiss it as we have the money, should be treated as considerably frightening for shareholders. What secret information regarding software etc; has been stolen? They probably have no idea.
Will keep on the watchlist for now, Australian contract win announced today, but would expect confirmation of a serious reorganization regarding security before investing in them.

Burg1: Thin trade before Christmas, potential II buyers working from home. Quite likely that investment decisions are being deferred until Jan. Enjoy your holiday, most importantly, wishing all good health.

Unlikely we will hear from Beeks before March. The move to the larger premises is scheduled for February. Omicron variant a potential worry regarding international travel, though vaccines and previous infections do appear to offer protection.
Read a trading update last month from a financial information supplier, they were losing two major clients. One of them opting for a comprehensive package from another supplier, instead of renewal when their contract ends. Can't say that this has anything to do with Beeks going forwards, which is why I did not keep the actual rns. Am determined to hold onto my shares, though not suggesting anybody should buy on my say so. Somebody with better knowledge than I, of these businesses will probably know of which company I'm referring to. That said they might not be able to enlighten further for obvious reasons.

DYOR as always before making any financial decision

Will hold on before deciding on a further buy. The intention is to pay 1.75p for the year, they have the cash. Therefore 29p a share returns 6%, most likely that the sp will rise before 6 Jan.

This is the current plan, with plenty of room for further developments in Europe and North America.

Global manufacturing strategy
Gelion’s manufacturing strategy is to implement the zinc-bromide manufacturing methodology with selected
PbA partners throughout the globe to supply targeted countries.
To facilitate speed to market, Gelion has signed two manufacturing and distribution partnership agreements
– one in Australia and one in India – which can supply multiple countries globally.
Indian and Australian manufacturing, absent of any further macro-economic disruption, is expected to
commence in 2022 and 2023. In parallel, Gelion aims to sign additional PbA partners to service the North
America, UK and European markets.

Existing Partners

HBL POWER SYSTEMS (India)
HBL Power Systems Limited (HBL) is a significant manufacturer and supplier of PbA batteries in India. It
also has presence in North America and Europe providing strategic manufacturing hubs for Gelion’s
products. HBL has been in business for more than 40 years; is listed on India’s stock market; and provides
batteries for customers across many applications targeted by Gelion.
Gelion and HBL have executed a manufacturing and distribution agreement, whereby Gelion receives a
royalty fee per kWh of batteries manufactured and sold by HBL in the Indian market.
The agreement also enables HBL to contract-manufacture Gelion’s batteries to be sold by Gelion or other
partners in countries outside of India.

BATTERY ENERGY POWER SOLUTIONS (Australia)
Battery Energy is a manufacturer and distributor/integrator of advanced PbA battery systems, headquartered
in Sydney, Australia. Battery Energy also has a dual, fully scalable manufacturing presence in China and
provides grid connected and off-grid batteries to Australian blue-chip companies, such as Telstra.
Gelion and Battery Energy have executed a manufacturing and distribution agreement whereby Gelion will
receives a royalty fee per kWh of batteries manufactured and sold by Battery Energy in the Australian and
New Zealand markets.

Basic details of current MOU's that will require successful field trials in order to be converted into orders

ARMSTRONG CAPITAL (UK)
Armstrong is a UK-based impact investor that has arranged funding for more than 350 MW of solar projects
in the UK and India. Armstrong’s investors were involved in earlier stage investments in Gelion. Armstrong
has a 200 MWh off-take memorandum of understanding (MoU) for Gelion’s batteries targeting deployment
in the UK and additional countries.
Under an MoU, dated 4 April 2019, Gelion has agreed to provide a beta version of the Endure battery to
Armstrong for testing. Subject to the results of the trials of the Endure battery, the parties have agreed to
develop an agreement for an order by Armstrong for an initial 200MWh of the Endure product to be delivered
during the period of four years following the date of the MoU.

WEGEN (Philippines)
WeGen is a Philippines-based company deploying solar PV renewable energy solutions. WeGen has a 100
MWh off-take MoU for Gelion’s batteries targeting grid connect and off-grid deployments on the islands to
replace energy produced by polluting diesel gen-sets.

MAYUR RESOURCES (Australia)
Mayur Resources is an Australian Stock Exchange (ASX) listed resources and energy company with projects
focused in Papua New Guinea (PNG). Mayur has a 100 MWh off-take MoU for Gelion’s batteries to support
its projects in PNG. Mayur is also Gelion’s distributor for PNG.

Global European Renewable Energy Company
In Q1 2021, Gelion was selected, after a worldwide search for breakthrough batteries, by a leading global
renewable energy company headquartered in Europe. The company deploys large scale solar PV farm,
wind farm and grid-scale energy storage solutions. The company will test and trial Gelion’s batteries in
Europe in 2022 and, based on success, may enter a commercial arrangement to deploy Gelion’s batteries
in selected projects globally.

Profit taking, panic. Going to over 300p so quickly, was crazy. Have ended up with a lot more shares through selling and buying. Will hold on to them regardless now, awaiting news of field trials, probably in the second half of next year. Meanwhile, there is a probability of more projects being announced, contingent on these trials.

December, January, February ..... just a matter of patience. The appointment of the Chief Medical Officer was strategic but only happened last month.

Going back to the rns of Nov 15, am still heartened by the CMO's statement, particularly the closing words:

Dr Todd Druley, Chief Medical Officer, ANGLE, added:

"I am extremely excited to join ANGLE as I believe the Company's patented technology has the potential to improve outcomes for cancer patients worldwide. I look forward to progressing ANGLE's strategy to demonstrate the high medical value of this leading liquid biopsy solution. I am confident that my clinical and industry experience will help to guide the clinical application and future regulatory approvals for the Parsortix system."

Regardless of when, here's wishing the company and all AGL holders a happy Christmas and a prosperous new year.

Was pleased to not find a rns, about shares purchased yesterday. The sp is currently up, though that could be down to buyback, therefore in my opinion not a reason to get too hopeful yet. I still believe that the thinking is to buy shares being sold by Index trackers, as a surplus of sales will even out the buys, therefore not inflating the price bought.
Likely that the next trading update will be Mid-Jan, DARK will have a fair idea now, of what the numbers will be. Therefore could be a very good strategy. That said, it only works well, if they are able to buy the shares cheaply. Therefore am hoping that the sp stays down until they achieve their objective.

It looks as if the sp could settle down now around 210-230p. Can't see the price sticking @over 300p until the field trials have concluded with a successful outcome *. That's when it will become interesting with news of license deals with battery manufacturers in Europe and America most likely.

* Gelion have confidence in this battery, though that is no guarantee of success. These trials are very important, for the company and investors alike.

Mon, 09/20/2021 - 14:17 -- Paul Crompton

Renewable-energy storage firm Gelion Technologies and lead-acid battery maker Battery Energy Power Solutions will partner to manufacture and commercialise non-flow zinc-bromide systems in Australia.

The partnership represents the next stage of commercialisation for Gelion. With the stationary batteries due to be deployed in production trials next year ahead of commercial availability.

Battery Energy will provide manufacturing scale-up of Gelion’s Endure battery at its site in Sydney, Australia.

https://www.bestmag.co.uk/indnews/gelion-partners-lead-battery-makers-build-zinc-bromine-esss-australian-market

Buyback? Probably to mop up the shares being released by FTSE100 index funds. The demand for FTSE250 shares will be much less. Likely at some point that DARK might need to raise some money. Buying shares is reducing their available cash, could well encourage shorting.

Personally, would rather see the shares fall a bit more short term.

Amazed by the demand for shares of this company over the last few days. Not much sign of ramping in the UK. Had a look on the web and found this article, link below, on MotleyFool in Australia. Likely disappointment that Gelion not floated on the ASX. Though on checking, find it would be cheap and easy for Australians to buy this much anticipated stock, GELN, on a number of platforms.
I expect that this stock is likely to settle down over £2 for now, not for me to guess how high. There are planned field trials starting early in 2022, three already planned projects dependent on positive results. From a UK perspective if they are successful, I would hope that we see adoption and manufacture of these batteries here in the UK. Due to the potential huge benefit they can provide in delivering an even supply of renewable power and in terms of national security.

https://www.fool.com.au/2021/09/10/if-only-gelion-was-an-asx-share-heres-why-its-batteries-are-making-news/

The 10% is likely to be the gel used to make the Gelion Endure battery. It is this gel that makes the battery special. Perfect for storing renewable energy for when it is needed such as night lighting. This battery is tough, can be drained 100% without doing any damage.

https://gelion.com/gelion-endure-battery/

On my radar because of finnCap involvement. It looks to have a good future. The sp is shooting up on modest private investor buys presently. Danger of institutional investors selling for an easy profit. Will be interesting to see how the market reacts when Gelion issues some news upgrades.

IPO 30 November 21 @145p - finnCap Nominated Adviser and Sole Broker

https://www.lse.co.uk/rns/GELN/admission-to-aim-and-first-day-of-dealings-64pup87fg4oqhcc.html

Already @200p now 205p to buy - This is a company that is attracting attention, potentially high growth with a need to raise more funding down the line. Potentially a good client for finnCap.

Many thanks for your contribution gf. Much more important than waffle from the likes of me. I take it, that you will be back again next year.

C'mon Charles,

"I thought some one said not approved" - That was you!

fast ducky ; - )

If the matter doesn't get resolved any time, it will be a continuing opportunity to short DARK. Am not advocating throwing ML to the wolves, though it is becoming clearer that the current situation is neither beneficial to shareholders, nor the majority of staff at DARK, who have no connection with Automony whatsoever.
The possibility of further action being taken against other former Autonomy employees, now with DARK, should whistleblowing testimony lead to that, can't be ruled out. Can you imagine how much damage that will do?

In the event of extradition being denied by HM Government, there could well be an anti-DARK response to that, from the US side of this affair. The thinking being, you might think that you can escape justice but we can punish you in other ways. The consequence of that don't bear thinking about, if one is a DARK shareholder. Even early investors, who most likely know ML well, could start to feel nervous at the prospect.

Am not in a position to make any sort of judgement on the Mike Lynch/Autonomy history. What is likely though is institutional investors becoming increasingly disillusioned with the current DARK bod. If the share price fails to get back above £6 despite good news from the company. It will indicate that trust with many of the current board has broken. That will lead to pressure for change at the top. A new CEO with the mandate to sweep out staff with a tainted history, would restore confidence in DARK among investors. Eventually even those with an Automony background and no doubt holding shares, will come to realise that it is in their own material interest for this to happen. As it will surely take away the downward pressure on the sp. If there is no movement before next year's AGM, the clamour (7% yesterday) for change is likely to become a revolt.

That said the sp has the smell of being near the bottom but can we trust the numbers we have been given?